Dianthus Therapeutics Investor Relations Material
Latest events
M&A Announcement
Dianthus Therapeutics
Q2 2025
7 Aug, 2025
Q1 2025
12 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Dianthus Therapeutics Inc
Access all reports
Dianthus Therapeutics Inc., operating under the ticker DNTH, is a clinical-stage biotechnology company based in New York, New York. The company focuses on designing, developing, and delivering innovative monoclonal antibodies intended for the treatment of severe autoimmune and inflammatory diseases. Their key developmental product is DNTH103, currently in clinical trials, targeted at conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Latest articles
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
Ticker symbol
DNTH
Country
🇺🇸 United States